These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 30045977)

  • 61. Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.
    Wang X; Bondar VV; Davis OB; Maloney MT; Agam M; Chin MY; Cheuk-Nga Ho A; Ghosh R; Leto DE; Joy D; Calvert MEK; Lewcock JW; Di Paolo G; Thorne RG; Sweeney ZK; Henry AG
    Elife; 2023 Oct; 12():. PubMed ID: 37874617
    [TBL] [Abstract][Full Text] [Related]  

  • 62. LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.
    Bae EJ; Kim DK; Kim C; Mante M; Adame A; Rockenstein E; Ulusoy A; Klinkenberg M; Jeong GR; Bae JR; Lee C; Lee HJ; Lee BD; Di Monte DA; Masliah E; Lee SJ
    Nat Commun; 2018 Aug; 9(1):3465. PubMed ID: 30150626
    [TBL] [Abstract][Full Text] [Related]  

  • 63. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
    Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
    Elife; 2020 Feb; 9():. PubMed ID: 32057291
    [TBL] [Abstract][Full Text] [Related]  

  • 64. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Leucine-rich repeat kinase 2 and Parkinson's disease.
    Kang UB; Marto JA
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
    Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-dose radiation decreases Lrrk2 levels in the striatum of large mammalian brains: New venues to treat Parkinson's disease?
    Iacono D; Murphy EK; Stimpson CD; Perl DP; Day RM
    Parkinsonism Relat Disord; 2024 Jul; 124():107024. PubMed ID: 38843617
    [TBL] [Abstract][Full Text] [Related]  

  • 69. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
    Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E
    Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Detection of Substrate Phosphorylation of LRRK2 in Tissues and Cultured Cells.
    Ito K; Xu L; Ito G; Tomita T
    Methods Mol Biol; 2021; 2322():53-61. PubMed ID: 34043192
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes.
    Unapanta A; Shavarebi F; Porath J; Shen Y; Balen C; Nguyen A; Tseng J; Leong WS; Liu M; Lis P; Di Pietro SM; Hiniker A
    J Biol Chem; 2023 Oct; 299(10):105192. PubMed ID: 37625589
    [TBL] [Abstract][Full Text] [Related]  

  • 74. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss.
    Ho DH; Nam D; Seo M; Park SW; Seol W; Son I
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269482
    [TBL] [Abstract][Full Text] [Related]  

  • 75. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain.
    Dhekne HS; Yanatori I; Gomez RC; Tonelli F; Diez F; Schüle B; Steger M; Alessi DR; Pfeffer SR
    Elife; 2018 Nov; 7():. PubMed ID: 30398148
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson's disease.
    Khan SS; Jaimon E; Lin YE; Nikoloff J; Tonelli F; Alessi DR; Pfeffer SR
    Proc Natl Acad Sci U S A; 2024 Aug; 121(32):e2402206121. PubMed ID: 39088390
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.
    Slone SR; Lavalley N; McFerrin M; Wang B; Yacoubian TA
    Neurobiol Dis; 2015 Jul; 79():1-13. PubMed ID: 25862939
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
    Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
    Ito G; Utsunomiya-Tate N
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.